The FDA has signed off on Compugen’s (NASDAQ:CGEN)
IND for a Phase 1/2 study evaluating the combination of COM701, an
anti-PVRIG antibody, Bristol Myers Squibb’s Opdivo (nivolumab) and
BMS-986207, the latter’s anti-TIGIT antibody, in patients with advanced
solid tumors.
The trial, expected to launch in H2, will also
accelerate the clinical evaluation of Compugen’s DNAM axis hypothesis
and biomarker-driven approach in advanced solid tumors to broaden
patient population response to cancer immunotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.